Immunobody22 Jan 2019 14:47
Yeah, the lack of a deal on Immunobody on the back of such a successful SCIB1 trial must have been a bitter pill for the BOD to swallow.
So, onwards and upwards with combo trials for both SCIB1 and SCIB2.
If successful, and hard to see reasons why not, this gives triple validation of Immunobody and hence a potentially far larger deal.
A good deal with BionTech may well give Scancell the luxury of waiting until the results of these 2 trials are well beyond any doubt.